Determination of carboplatin in canine plasma by high-performance liquid chromatography
Article first published online: 29 DEC 2009
Copyright © 2009 John Wiley & Sons, Ltd.
Volume 24, Issue 8, pages 908–913, August 2010
How to Cite
Villarino, N., Cox, S., Yarbrough, J. and Martín-Jiménez, T. (2010), Determination of carboplatin in canine plasma by high-performance liquid chromatography. Biomed. Chromatogr., 24: 908–913. doi: 10.1002/bmc.1385
- Issue published online: 14 JUL 2010
- Article first published online: 29 DEC 2009
- Manuscript Accepted: 18 NOV 2009
- Manuscript Revised: 13 NOV 2009
- Manuscript Received: 7 MAY 2009
Carboplatin is an antineoplastic drug administered to treat different tumoral conditions in canine oncology. The objective of this study was to validate a high-performance chromatographic (HPLC) method which could be applied in canine pharmacokinetic studies. Following ultrafiltration using a Centrifree device, standards, quality controls and plasma samples were separated by isocratic reversed-phase HPLC on an Inertsil ODS-2 (250 × 4.6 mm i.d.) analytical column and quantified using UV detection at 220 nm. The mobile phase was potassium phosphate (pH 4.5), with a flow-rate of 1.0 mL/min. The procedure produced a linear curve (r2 > 0.999) over the concentration range 1–200 μg/mL. The lower limit of quantification was 1 μg/mL. The intra-assay and inter-assay precision was ∼90%. The overall recovery was ∼90%. The method was illustrated with a preliminary pharmacokinetic analysis on nine dogs treated with carboplatin at our hospital. Carboplatin disposition followed a monocompartmental structure in dogs and was characterized by a short half-life (50 min). Copyright © 2009 John Wiley & Sons, Ltd.